INTRODUCTION
============

The prognosis of breast cancer is usually determined by the disease stage (TNM stage) after surgery that assesses the size of tumor (T), the status of metastasis to adjacent lymph nodes (N), and the presence or absence of distant metastasis to other organs (M). The prognosis of patients classified according to TNM stage is different even in the same stage. In other words, in the same stage of breast cancer, the prognosis depends on the expression of estrogen or progesterone receptor (ER or PR) and the over-expression of HER2 protein or the amplification of the gene. Therefore, some investigators have proposed a new staging system for breast cancer including such prognostic factors mentioned above ([@B1]).

So far, the over-expression of HER2 protein or the amplification of the gene has been recognized as a prognostic factor of breast cancer and to be associated with poor prognosis ([@B2]-[@B7]). However, it has been also claimed that the prognostic significance of HER2 is found not in all breast cancer, but only in advanced cases with lymph node metastasis ([@B8]). Thus, it is still a controversial issue. Recently, the therapeutic effect of the targeted therapy using trastuzumab for breast cancer has been approved in adjuvant setting ([@B9], [@B10]). So, the clinical significance of HER2 is increased in the determination of indication for targeted therapy as well as of prognosis of breast cancer.

Test methods to assess HER2 status are diverse from gene level to protein level. Immunohistochemistry (IHC) for the detection of HER2 proteins is relatively easy, simple, cheap, and thus performed widely, but has a great shortcoming of the variable interpretation of the same results, i.e., lack of objectivity of results. Therefore, for a vague result obtained by immunohistochemical staining method, it is recommended to assess the accurate status of *HER2* gene amplification by performing fluorescence in-situ hybridization (FISH) because its accuracy and reliability are high, even though expensive ([@B11]-[@B13]). Therefore, the results by FISH are more significant than that of IHC in determination of effects of HER2 on the prognosis of breast cancer.

In this study, we performed FISH for the detection of *HER2* gene amplification and investigated the prognostic significance of HER2 according to the stages of breast cancer.

MATERIALS AND METHODS
=====================

Subjects
--------

Among the cases of patients underwent mastectomy for breast cancer with invasive ductal carcinoma (NOS) at our institution from January 1994 to December 1999, 338 cases were enrolled in this study who were available for the retrospective examination of medical records and the follow-ups as well as feasible for the amplification of *HER2* gene test with good condition of the stored paraffin-embedded tissues. The subjects had never been treated with trastuzumab before this study and had a sufficient follow-up period.

Methods
-------

### Preparation of tissue array

The area representing the histological finding of breast cancer in the paraffin-embedded tissues of each case was assessed by microscope, and from the area, tissues were obtained using a punch 3 mm in diameter, and 30 cases of tissues per array block were aligned.

### Test for amplification of *HER2* gene by fluorescence in situ hybridization

The paraffin-embedded tissue array blocks were sectioned at 4 µm thickness, attached to slides, and after performing the deparaffinization and hydration process, using a commercialized *HER2* FISH kit (Vysis Inc, Downers Grove, Ill), experiments were performed according to the guideline of the manufacturer. First, the samples were treated with diluted wash buffer for 2 min, treated with pre-treatment solution at 95-99℃ for 10 min, and washed with wash buffer for 3 min twice. The samples were treated with pepsin reagent for 10 min, washed with wash buffer for 3 min twice, and dehydrated. Subsequently, the samples were treated with HER2/CEN-17 Probe Mix at 82℃ for 5 min, incubated in a 45℃ humidified hybridization chamber for 14-20 hr, and treated with stringent wash buffer at 65℃ for 10 min. Washed again with wash buffer for 3 min twice, the samples were dehydrated, and a fluorescent mounting solution containing 4\'-6-diamidine-2-phenylindole (DAPI) was applied to slides and read. In normal cells, CEN-17 DNA probe bound to the centromere area of chromosome 17 and thus 1-2 green fluorescent signal was shown, and *HER2* DNA probe bound to the *HER2* gene and thus 1-2 red fluorescent signal was shown, and the cases whose HER2/CEN-17 ratio was higher than 2 were considered to be positive for the amplification of *HER2* gene.

### Survival survey and survival analysis

Through the examination of the medical records of the subject patients and the records of the visit to our outpatient clinic, the survival status of patients was assessed, and for patients who did not have the record of the visit to hospital for longer than 6 months, the survival survey was performed by telephone. The analysis of the survival of patients was performed by obtaining the Kaplan-Meier survival curve. Comparing and analyzing survival data by Log-rank test. The determination of independent prognostic factors on the survival was performed by multivariate analysis by applying Cox regression model. A *p* value less than 0.05 was considered to be statistically significant.

RESULTS
=======

Characteristics of the subjects
-------------------------------

The median age of the entire subjects was 48 yr, and the median duration of follow-ups was 6.3 yr ([Table 1](#T1){ref-type="table"}). With regard to the distribution of the stages of breast cancer, the stage I was 58 cases (17.2%), the stage II was 184 cases (54.4%), and the stage III was 96 cases (28.4%), and concerning surgical treatment, mastectomy was performed on 301 cases (89.0%), and postoperative adjuvant chemotherapy and hormone therapy were performed by considering the status of lymph node metastasis and hormone receptor test. In the status of hormone receptors of breast cancer, of 288 tested cases, 190 cases (66.0%) were found to be positive, and in the HER2 test by FISH of breast cancer, positive results meaning the amplification of the *HER2* gene was shown in 89 cases of the total 388 cases (26.3%).

Results of HER2 test according to the stage
-------------------------------------------

In 89 cases showing the result of the amplification of *HER2* gene in breast cancer, the positivity was examined according to the stage ([Table 2](#T2){ref-type="table"}). The positive result was detected in 6 cases of the stage I (10.3%), 41 cases in the stage II (22.3%), and 42 cases in the stage 3 (43.8%), hence, it was found that the positive rate became higher as the disease stage progressed.

Survival analyses according to the stage
----------------------------------------

In the survival analysis based on the disease-free period, the 5-yr survival rate according to the amplification of *HER2* gene showed different results among the stages of breast cancer ([Fig. 1](#F1){ref-type="fig"}). In the stage I breast cancer, the 5-yr disease-free survival (DFS) rate of the *HER2* gene positive group was 100%, the survival rate of the negative group was 85%, and the survival rate of the positive group was higher, but it was not statistically significant (*p*=0.2053). In the stage II breast cancer, the 5-yr DFS rate of the positive group was 85%, that of the negative group was 87%, and a difference was not significant (*p*=0.3855). However, in the stage III breast cancer, the DFS rate of positive group was 41%, that of the negative group was 70.5%, and the DFS rate of the *HER2* gene-positive group was significantly lower (*p*=0.0090).

In the survival analysis based on the overall survival period, similarly, the 5-yr survival rate according to the amplification of *HER2* gene showed different results depending on the stages of breast cancer ([Fig. 2](#F2){ref-type="fig"}). In the stage I breast cancer, the 5-yr overall survival (OS) rate of the *HER2*-positive group was 100% and that of the negative group was 94%. In the stage II breast cancer, the OS rate of the positive group was 88% and that of the negative group was 92.5%, and the difference was not significant (*p*=0.5927 in the stage I, *p*=0.8566 stage II). However, in the stage III breast cancer, the 5-yr OS rate of the *HER2*-positive group was 28% and that of the negative group was 60%, and the difference was significant (*p*=0.0034).

Prognostic factors influencing survival
---------------------------------------

To examine prognostic factors that independently influence the disease-free survival and the overall survival, multivariate analysis was performed by Cox regression model ([Table 3](#T3){ref-type="table"}). As an important prognostic factor influencing recurrence and death, the statistical significance of the positive finding of HER2 was confirmed. The risk of recurrence of the *HER2* gene amplification-positive group was 1.669 times higher than that of the negative group (*p*=0.036), and the risk of death was 2.394 times higher (*p*=0.003). On the other hand, in the same analysis performed according to the disease stage, the amplification of *HER2* gene did not show any significant effect on recurrence and survival in the disease stage I and II breast cancer, but in the stage III breast cancer, increased the risk of recurrence by 2.678 times (*p*=0.002) and the risk of death by 2.576 times (*p*=0.005). Therefore, the significance as a prognostic factor could be confirmed only in the stage III breast cancer ([Table 4](#T4){ref-type="table"}).

DISCUSSION
==========

The significance of this study is that the amplification of the *HER2* gene, which has been reported to be closely associated with the prognosis of breast cancer, was re-examined and the effect on the prognosis of the same stage breast cancer was assessed by survival analysis based on the long-term follow-ups over than 5 yr. As mentioned already in the introduction, to raise the reliability of HER2 test, in our study, HER2 results were assessed by gene amplification test using FISH, which could be also considered to be greatly meaningful for the understanding of the significance HER2 as a prognostic factor. However, this study was performed retrospectively and the number of patients in stage I was relatively small to that of other stages due to the retrospective selection of appropriate tissues of breast cancer for *HER2* FISH test and survival analyses. These would be a limitation of this study.

Generally, the positive rate of HER2 in breast cancer has been reported to be 20-30% ([@B14]-[@B17]), and in our study, similarly, the positive rate of the amplification of *HER2* was found to be 26.3%, and thus it could be confirmed. Nevertheless, *HER2*-positive rate showed a difference depending on the stage of breast cancer, and the positive result was shown in 10.3% in the stage I, 22.3% in stage II, and 43.8% in the stage III. This result suggests that as the disease stage of breast cancer is advanced, HER2-positive rate increases, and HER2 positivity is closely associated with high stage of breast cancer, that is, poor prognosis ([@B18]-[@B20]).

According to the summary of HER2 of breast cancer reported until 1998 by Revillion et al. ([@B18]), HER2-positive result was a marker representing the aggressiveness of tumors and showed poor prognosis, nonetheless, because of the association with other strong prognostic factors, it did not have a clinically important significance. Slamon et al. ([@B16]) and Tandon et al. ([@B21]) have reported that the amplification of the *HER2* gene in breast cancer assessed by Southern blot had been associated with poor prognosis and these results had been found only in the lymph node positive group, but not in the lymph node negative group. These results are similar to our results in this study. We stratified the patients not by nodal status but by stages of breast cancer to exclude the influence of other prognostic factors such as tumor size, hormonal status as well as nodal status. In this study the pure prognostic effect of *HER2* gene amplification was noted only in stage III patients of breast cancer, not in stage I or II. We could suggest an explanation for these results that the advance of breast cancer would be associated with the increased amplification of the *HER2* gene and the longer duration of *HER2* gene action than in early breast cancer ([@B22]), therefore, stage III of breast cancers in this study might have taken sufficient chances to express harmful effects on their survival not only by *HER2* signal transduction pathway but also by crosstalks with other signal transduction pathways such as ER pathway.

On the other hand, Borg et al. ([@B23]) have reported that, with the result obtained by the same method, the amplification of *HER2* gene did not influence prognosis in both lymph node -positive and -negative group. Afterwards, in numerous results applied immunohistochemical staining method, similar results were shown ([@B24], [@B25]), and until now, a clear conclusion could not be reached and it is a controversial issue.

HER2 as a prognostic factor assessed by multivariate analysis, the amplification of the *HER2* gene was confirmed to increase the risk of recurrence by 1.669 times (*p*=0.0036), and the risk of death by 2.394 times (*p*=0.002) in overall cases of breast cancer. However, our result showed that the effect of the amplification of *HER2* gene differs depending on the disease stage. In other words, the prognosis of the *HER2* gene amplification group was poor only in the stage III breast cancer, and in the stage I and II breast cancer, a statistically significant difference from the negative group was not detected. In multivariate analysis performed according to the stage of breast cancer, as the disease stage is advanced, the amplification of the *HER2* gene was associated with a high risk level of death, however, the statistical significance was noted only in the stage III breast cancer. Therefore, based on the result of our study, it could be confirmed that the amplification of the *HER2* gene exerts a poor effect only on the prognosis of advanced breast cancer.

In conclusion, the amplification of the *HER2* gene in breast cancer confirmed by FISH was associated with the progression of the disease stage of breast cancer, and the clinical significance as a prognostic factor might be confined only in advanced breast cancer.
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###### 

Clinicopathological characteristics of 338 cases of breast cancer
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MRM, modified radical mastectomy; BCS, breast-conserving surgery; ER, estrogen receptor; PR, progesterone receptor; FISH, fluorescence in situ hybridization.

###### 

*HER2* gene amplification according to the stages of breast cancer
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FISH, fluorescence in situ hybridization.

###### 

Multivariate analyses for disease-free survival and overall survival in all cases (Cox regression model)
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RR, relative risk; C.I., confident interval; DFS, disease-free survival; OS, overall survival; ER, estrogen receptor; FISH, fluorescence in situ hybridization.

###### 

Multivariate analyses of disease-free survival and overall survival according to the stages of breast cancer
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DFS, disease-free survival; OS, overall survival; RR, relative risk; C.I., confidence interval; ER, estrogen receptor; FISH, fluorescence in situ hybridization.
